GSK Says Immune Response from mRNA Flu Shot Surpasses Licensed Competitors
GSK moves its dual-target mRNA seasonal flu vaccine to Phase 3 trials following strong Phase 2 data and FDA Fast Track status.
GSK's new flu shot made by mRNA (a newer vaccine technology) showed really good results in early testing, so they can now test it on more people. When a medicine does well in testing and moves forward, it shows the company might have something valuable, but we don't know yet if it will actually work as well for everyone.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.